Tempus time network expands support of phase i clinical trials to accelerate activation and enrollment

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, is leveraging its time network to expand its support in phase i clinical trials. since its inception in 2019, time has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the u.s. to further expand its support of phase i trials, tempus has formed the t.
TEM Ratings Summary
TEM Quant Ranking